AwesomeCapital
Search This Blog
Thursday, June 5, 2025
Ocugen to License Modifier Gene Therapy for Retinitis Pigmentosa in Korea
Upfront fees and near-term development milestone payments totaling up to $11 million
Sales milestones of $150 million or more in first 10 years of commercialization
Royalties equaling 25% of net sales
Ocugen to manufacture and supply OCU400
https://finviz.com/news/74039/ocugen-inc-announces-signing-of-binding-term-sheet-for-the-license-of-ocu400-modifier-gene-therapy-for-retinitis-pigmentosa-in-korea
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.